Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Biologists discover process that neutralises tumours

Researchers from the University of California San Diego have identified an unexpected mechanism that could help determine whether a cancer patient will respond to immunotherapy.

Ideally, the immune system identifies tumours as threatening elements and deploys immune cells (T cells) to find and kill them.

However, tumour cells have evolved to employ a protein called PD-L1 to blind T cells from carrying out their functions and evade immune defenses.

PD-L1 protects tumour cells by activating a "molecular brake" known as PD-1 to stop T cells.

In important therapeutic progress, antibodies developed to block PD-L1/PD-1 have been clinically proven to benefit certain cancer patients.

Yet why some patients don't respond to such therapy has remained a mystery. Now, UC San Diego's Yunlong Zhao, Enfu Hui and their colleagues at the University of Chicago and the Nanjing Medical School in China have uncovered some clues.

As described in the journal Cell Reports, the researchers discovered an unexpected twist in the tumour versus T cell battle.

Some tumour cells display not only their PD-L1 weapon, but also the PD-1 "brake."

This simultaneous expression leads PD-1 to bind and neutralize PD-L1 on the same tumour cell.

Thus, the PD-L1 on these tumour cells can no longer engage the PD-1 brake on T cells.

"It's a very exciting finding," said Hui. "Our study uncovered an unexpected role of PD-1 and another dimension of PD-1 regulation with important therapeutic implications."

This study suggests that patients with high levels of PD-1 on tumour cells may not respond well to the blocking antibodies because the PD-1 pathway is self-canceled.

In these patients, mechanisms other than PD-L1/PD-1 are likely employed by the tumours to escape from immune destruction.

Looking to extend the immunotherapy potential of the finding, Hui and his colleagues are now seeking to determine additional mechanisms of "self-cancellation" at the interface of the tumour and immune cells.

"We think that our finding is the tip of the iceberg," said Hui, recently named a Pew Biomedical Scholar and Searle Scholar. "We speculate that self-cancellation is a general mechanism to regulate immune cell function. Understanding these processes more clearly will help develop better immunotherapy strategies and more reliably predict whether a patient will respond or not."

Source: University of California - San Diego

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence